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LETTERS TO THE EDITOR 
Myocardial Metabolism of Hypertropbic 
Cardiomyopathy and Glucose Uptake 
The recent article by Grover-McKay et al. (I) makes very interest- 
ing observations on the myocardial metabolism of hypertrophic 
cardiomyopathy. However, it also raises some concerns over the 
significance of glucose uptake in fasting subjects as imaged by 
positron emission tomography (PET). According to the study pro- 
tocol, patients were requested to fast overnight with PET scanning 
the following day. Figure I demonstrates homogeneous N-13 am- 
monia uptake throughout the myocardium but abnormal F-18 2- 
deoxyglucose uptake in the septum relative to the lateral wall. The 
authors characterize this study as showing normal F-18 2- 
deoxyglucose metabolism in the lateral wall and abnormal F-18 
2-deoxyglucose metabolism in the septum. Such analysis of a fasting 
F-18 2-deoxyglucose study is at variance with much of the published 
literature. 
Myocardial glucose utilization depends on a number of hormonal 
and metabolic factors. Fasting creates a metabolic situation favoring 
free fatty acid oxidation over carbohydrate oxidation (2). Normal 
myocardium in the fasting state, therefore, will extract relatively 
little glucose at rest. F-18 2-deoxyglucose mimics initial extraction 
of glucose and will also be taken up to a minimal degree by the 
myocardium at rest and in the fasting state (3,4). Conversely. in the 
nonfasted state. myocardial uptake of glucose, and therefore F-18 
2-deoxyglucose, is increased and imaging of normal myocardium is 
possible. Furthermore, Marshall et al. (5) were able to differentiate 
normal from ischemic tissue in the nonfasting state. As Gould (6~ 
points out in a recent editorial, fasting F-18 2-deoxyglucose studies 
are useful to detect ischemia because only ischemic tissue will take 
up F-18 2-deoxyglucose in the fasting state. In the nonfasting state, 
both ischemic and normal tissue can be visualized. 
The patient in Figure I may have “normal” F-18 2-deoxyglucose 
uptake in the lateral wall for several reasons: 1) normal tissue in a 
nonfasting state, 2) ischemic tissue in a fasting state, 3) globally 
abnormal glucose metabolism compared with known ischemic and 
nonischemic models. 
Do the authors believe that fasting and nonfasting glucose 
metabolism in hypertrophic cardiomyopathy is truly opposite to that 
seen in normal individuals, or were their patients not truly fasting? 
DAVID El. JOYCE, MD 
Division of Cordiok+y 
University Hocpitals of Ckwlnnd 
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Reply 
Joyce’s letter addresses an issue that is important for studies of 
myocardial metabolism with positron emission tomography (PET) 
and for interpretation of images of metabolism. At issue is myocar- 
dial F-18 2-deoxyglucose uptake in patients after an overnight fast as 
shown in Figure 1 of our recent article. As pointed out by Joyce, and 
as amply documented by others, myocardial glucose utilization 
depends on many factors (1,2). Levels of circulating glucose i,i 
plasma are an important determinant, as demonstrated initially by 
Bing et al. (3) and subsequently confirmed by Carlsten et al. (4). The 
myocardial extraction of glucose was found to be a function of the 
glucose plasma levels. These studies also demonstrated that when 
plasma fatty acid levels are high, as they are in the fasted state, as 
much as 6W to 70% of the oxygen consumption could be accounted 
for by oxidation of fatty acids. Importantly, the same studies 
reported myocardial utilization of glucose in the fasted state, al- 
though at lower rates compared with those in the post-absorptive 
state. The fact that myocardium continues to utilize glucose in the 
fasted state explains the observation of myocardial F-18 2- 
deoxyglucose uptake in our patients studied with PET after an 
overnight fast. Therefore, uptake of F-18 2-deoxyglucose in the 
lateral wall of the patient shown in Figure 1 of our article is indeed 
consistent with normal myocardium, one of three possible explana- 
tions suggested by Joyce. However. this uptake can be consistent 
with the fasting state, which is different from Joyce’s contention. 
The images shown in our report depict only the relative distri- 
bution of glucose utilization in myocardium and provide no infor- 
mation about absolute rates of glucose utilization. As observed by 
us and by olhers (5-7), glucose utilization in the fasted state may 
decline to levels at which uptake of F-18 2-deoxyglucose in normal 
myocardium can no longer be visualized on the cross-sectional PET 
images. In patients with coronary artery disease during exercise- 
induced ischemia, our experience with F-18 2-deoxyglucose (8) is 
consistent with findings by other groups as well as with animal 
experimental observations (7.9,10) that suggest preferential glucose 
utilization in ischemic and postischemic myocardium. F-18 2- 
deoxyglucose may be elevated in ischemic myocardium relative to 
normal myocardium or relative to blood flow in the ischemic 
segment. The latter point argues against Joyce’s second contention, 
that tracer uptake in the lateral wall represents ischemia. In addi- 
tion, tissue clearance kinetics of C-l 1 palmitate were similar in the 
septum and the lateral wall. Had ischemia been present in the lateral 
wall. we would have expected a regional decrease in the tissue 
clearance rate of C-l I activity and a decline in the early clearance 
curve component as we reported previously (I I, I?). 
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Because of the qualitative nature of the studies on myocardial 
glucose utilization in our report, it is not possible to exclude the 
third possibility of globally abnormal glucose metabolism as sug- 
gested by Joyce. However, there is no evidence in published studies 
or in this investigation to support such a notion. Rather, most of the 
available evidence in classic hypertrophic cardiomyopathy points to 
an abnormality affecting primarily the disproportionately thickened 
interventricular septum and not the lateral wag (13-16). Our studies 
with PET in patients with hypertrophic cardiomyopathy indicated 
that C-l 1 palmitate kinetics in the septum were similar to those in 
the lateral wall and to those in normal myocardium. suggesting that 
fatty acid metabolism was normally preserved. In contrast, the 
relative reduction of N-13 ammonia uptake in the septum compared 
with that in the lateral wall indicated a relative decrease in blood 
flow. Importantly, the even greater reduction (rather than an in- 
crease) in glucose utilization argues against the presence of ischemia 
in the interventricular septum. Our study offered one potential 
mechanism for this relative decrease in tracer uptake in the septum 
as compared with the lateral wall. However, this mechanism re- 
mains speculative at present. Our initial observations of this meta- 
bolic abnormality in patients with hypertrophic cardiomyopathy will 
require further investigations to elucidate the underlying mechanism 
or mchanisms. As new positron tracers are developed, it will be 
possible in the future to examine with positron emission tomography 
other aspects of substrate metabolism and of neural and hormonal 
control. This should provide further understanding of the patho- 
physiology underlying our observation. 
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Correction 
In Gottlieb et al. (J Am Coil Cardiol 1989;13:1534-9), the 
greater than and less than symbols in Tables 1 and 2 should 
be reversed. In the two columns headed ANP, “>” should 
appear as “<” and “<” should appear as “>“. 
